medigraphic.com
ISSN 0016-3813 (Impreso)

2019, Número 1

<< Anterior Siguiente >>

Gac Med Mex 2019; 155 (1)


Tratamiento de infección crónica por virus de hepatitis C en niños, ¿perspectiva hacia la curación o lejos de la meta?

Córdova-Gallardo J, Gómez-Toscano V, Dionicio-Avendaño AR, Jiménez-Escobar I

Idioma: Español
Referencias bibliográficas: 89
Paginas: 80-89
Archivo PDF: 263.62 Kb.


RESUMEN

La infección por el virus de hepatitis C es un problema global de salud pública; en México aproximadamente 2 % de la población se encuentra infectada. En niños, los datos de prevalencia son variables según la edad, pero se estima que 0.1 a 2 % de los niños presenta infección crónica por virus de hepatitis C, cuya principal vía de transmisión es la perinatal. Actualmente existen antivirales de acción directa aprobados en adultos con una tasa de respuesta viral sostenida superior a 95 %; sin embargo, en niños aún son pocos los estudios que confirman su seguridad y efectividad. Aunque todavía estamos lejos de la meta, avanzamos rápidamente hacia un tratamiento óptimo de curación también para pacientes pediátricos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol. 2013;19(44):7880-7888.

  2. Burguete-García AI, Conde-González CJ, Jiménez-Méndez R, Juárez- Díaz Y, Meda-Monzón E, Torres-Poveda K, et al. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Salud Publica Mex. 2011;53:S7-S12.

  3. Santos-López G, Sosa-Jurado F, Vallejo-Ruiz V, Meléndez-Mena D, Reyes-Leyva J. Prevalence of hepatitis C virus in the Mexican population: a systematic review. J Infect. 2008;56 281-290.

  4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.

  5. Squires JE, Balistreri W. Hepatitis C virus infection in children and adolescents. Hepatol Commun 2017;1:87-98.

  6. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012;54 838-855.

  7. Álvarez-Hernández G, Sotelo-Cruz N, Cano-Rangel A. Epidemiología del virus de la hepatitis C en niños. Rev Mex Pediatr. 2007;4:161-170.

  8. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol. 2012;18:99-104.

  9. Escobedo-Meléndez G, Fierro NA, Roman S, Maldonado-González M, Zepeda-Carrillo E, Panduro A. Prevalence of hepatitis A, B and C serological markers in children from western Mexico. Ann Hepatol. 2012;11:194-201.

  10. Broide E, Kimchi NA, Scapa E. Chronic hepatitis C infection in children. Minerva Gastroenterol Dietol. 2006;52:187-193.

  11. Narkewicz MR, Cabrera R, González-Peralta RP. The “C” of viral hepatitis in children. Semin Liver Dis. 2007;27:295-311.

  12. Yang CHT, Yoo ER, Ahmed A. The role of direct-acting antivirals in the treatment of children with chronic hepatitis C. J Clin Transl Hepatol. 2017;5:59-66.

  13. Viral Hepatitis Statistics and Surveillance. EE. UU.: Centers for Disease Control and Prevention; 2009.

  14. Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European paediatric hepatitis C virus infection. J Infect Dis. 2000;181:419-424.

  15. Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. J Med Virol. 2009;81 836-843.

  16. Spencer JD, Latt N, Beeby PJ, Collins E, Saunders JB, McCaughan GW, et al. Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. J Viral Hepat. 1997;4:395-409.

  17. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192:1880-1889.

  18. Syriopoulou V, Nikolopoulou G, Daikos GL, Theodoridou M, Pavlopoulou I, Nicolaidou P, et al. Mother to child transmission of hepatitis C virus: rate of infection and risk factors. Scand J Infect Dis. 2005;37:350-353.

  19. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002;36:S106-S113.

  20. Resti M, Bortolotti F, Vajro P, Maggiore G. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig Liver Dis. 2003;35:453-457.

  21. Abdel-Hady M, Bunn SK, Sira J, Brown RM, Brundler MA, Davies P, et al. Chronic hepatitis C in children--review of natural history at a National Centre. J Viral Hepat. 2011;18:e535-e540.

  22. Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol. 2004;19:1357-1362.

  23. Guido M, Rugge M, Jara P, Hierro L, Giacchino R, Larrauri J, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology. 1998;115:1525-1529.

  24. El-Shabrawi MH, Mohsen NA, Sherif MM, El-Karaksy HM, Abou-Yosef H, El-Sayed et al. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest. Eur J Gastroenterol Hepatol. 2010;22:946-951.

  25. Flores-Calderón J, Morán-Villota S, Ramón-García G, González-Romano B, Bojórquez-Ramos MC, Cerdán-Silva L, et al. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study. Ann Hepatol. 2012;11 364-368.

  26. Alkhouri N, Sedki E, Alisi A, Lopez R, Pinzani M, Feldstein AE, et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int. 2013;33:79-85.

  27. Behairy Bel-S, Sira MM, Zalata KR, Salama el-SE, Abd-Allah MA. Transient elastography compared to liver biopsy and morphometry for predicting fibrosis in pediatric chronic liver disease: Does etiology matter? World J Gastroenterol. 2016;22:4238-4249.

  28. Lewindon PJ, Balouch F, Pereira TN, Puertolas-Lopez MV, Noble C, Wixey JA, et al. Transient liver elastography in unsedated control children: Impact of age and intercurrent illness. J Paediatr Child Health. 2016;52:637-642.

  29. Engelmann G, Gebhardt C, Wenning D, Wühl E, Hoffmann GF, Selmi B, et al. Feasibility study and control values of transient elastography in healthy children. Eur J Pediatr. 2012;171 353-360.

  30. Franchi-Abella S, Corno L, Gonzales E, Antoni G, Fabre M, Ducot B, et al. Feasibility and diagnostic accuracy of supersonic shear-wave elastography for the assessment of liver stiffness and liver fibrosis in children: a pilot study of 96 patients. Radiology. 2016;278:554-562.

  31. Dhyani M, Gee MS, Misdraji J, Israel EJ, Shah U, Samir AE. Feasibility study for assessing liver fibrosis in paediatric and adolescent patients using real-time shear wave elastography. J Med Imaging Radiat Oncol. 2015;59:687-694

  32. De-Lédinghen V, Le-Bail B, Rebouissoux L, Fournier C, Foucher J, Miette V, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr. 2007;45:443-450.

  33. Breton E, Bridoux-Henno L, Guyader D, Daniélou H, Jouan H, Beuchée A, et al. Value of transient elastography in noninvasive assessment in children’s hepatic fibrosis. Arch Pediatr. 2009;16:1005-1010.

  34. Yang LY, Fu J, Peng XF, Pang SY, Gao KK, Chen ZR, et al. Validation of aspartate aminotransferase to platelet ratio for diagnosis of liver fibrosis and prediction of postoperative prognosis in infants with biliary atresia. World J Gastroenterol. 2015;21:5893-5900.

  35. Shen QL, Chen YJ, Wang ZM, Zhang TC, Pang WB, Shu J,et al. Assessment of liver fibrosis by Fibroscan as compared to liver biopsy in biliary atresia. World J Gastroenterol. 2015;21:6931-6936.

  36. Hukkinen M, Kivisaari R, Lohi J, Heikkilä P, Mutanen A, Merras-Salmio L, et al. Transient elastography and aspartate aminotransferase to platelet ratio predict liver injury in paediatric intestinal failure. Liver Int. 2016;36:361-369.

  37. Leung DH, Khan M, Minard CG, Guffey D, Ramm LE, Clouston AD, et al. Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease. Hepatology. 2015;62:1576-1583.

  38. Pinto J, Matos H, Nobre S, Cipriano MA, Marques M, Pereira JM, et al. Comparison of acoustic radiation force impulse/serum noninvasive markers for fibrosis prediction in liver transplant. J Pediatr Gastroenterol Nutr. 2014;58:382-386.

  39. McGoogan KE, Smith PB, Choi SS, Berman W, Jhaveri R. Performance of the AST-to-platelet ratio index as a noninvasive marker of fibrosis in pediatric patients with chronic viral hepatitis. J Pediatr Gastroenterol Nutr. 2010;50:344-346.

  40. Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Marczyńska M. Is liver biopsy still needed in children with chronic viral hepatitis? World J Gastroenterol. 2015;21:12141-12149.

  41. Shneider BL, González-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: hepatitis B, C and NAFLD: summary of a single topic conference. Hepatology. 2006;44:1344-1354.

  42. Nydegger A, Srivastava A, Wake M, Smith AL, Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol. 2008;23:226-230.

  43. Rodríguez JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr. 2009;48:341-347.

  44. Garazzino S, Calitri C, Versace A, Alfarano A, Scolfaro C, Bertaina C, et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr. 2014;173:1025-1031.

  45. Omland LH, Krarup H, Jepsen P, Georgsen J, Harritshøj LH, Riisom K, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol. 2010;53 36-42.

  46. Rumbo C, Fawaz RL, Emre SH, Suchy FJ, Kerkar N, Morotti RA, et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr. 2006;43:209-216.

  47. Baker RD, Baker SS. Hepatitis C in children in times of change. Curr Opin Pediatr. 2015;27 624-628.

  48. González-Peralta RP, Langham MR, Andres JM, Mohan P, Colombani PM, Alford MK, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2009;48 630-635.

  49. Strickland DK, Jenkins JJ, Hudson MM. Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J Pediatr Hematol Oncol. 2001;23:527-529.

  50. Kelly D, Sharif K, Brown RM, Morland B. Hepatocellular carcinoma in children. Clin Liver Dis. 2015;19:433-447.

  51. Bhatia V, Seth S, Kapoor A, Sibal A. Incidentally detected hepatocellular carcinoma in cirrhotic children. Indian J Pediatr. 2014;81:826.

  52. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.

  53. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology. 2005;41:1013-1018.

  54. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967-972.

  55. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.

  56. Serranti D, Indolfi G, Resti M. New treatments for chronic hepatitis C: an overview for paediatricians. World J Gastroenterol. 2014;20:15965-15974.

  57. Sung H, Chang M, Saab S. Management of hepatitis C antiviral therapy adverse effects. Curr Hepat Rep. 2011;10:33-40.

  58. Narkewicz MR, Rosenthal P, Schwarz KB, Drack A, Margolis T, Repka MX, et al. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr. 2010;51:183-186.

  59. Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis. 2013;56 961-967.

  60. Jonas MM, Schwarz KB, Gonzalez-Peralta R, Lobritto S, Molleston JP, Murray KF, et al. Long-term growth outcomes in children treated for chronic hepatitis C. J Pediatr. 2014;165:1252-1254.

  61. Granot E, Sokal EM. Hepatitis C virus in children: deferring treatment in expectation of direct-acting antiviral agents. Isr Med Assoc J. 2015;17:707-711.

  62. Jonas MM, Balistreri W, González-Peralta RP, Haber B, Lobritto S, Mohan P, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology. 2012;56 523-531.

  63. Schwarz KB1, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology. 2011;140:450-458

  64. Sokal EM, Bourgois A, Stéphenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol. 2010;52:827-831.

  65. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010;52:501-507.

  66. El-Karaksy HM, Mogahed EA, El-Raziky MS, Saleh D, Besheer M, Mubarak S. Safety and efficacy of combined treatment with pegylated interferon alpha-2b and ribavirin for HCV Genotype 4 in children. J Interferon Cytokine Res. 2016;36:1-8.

  67. Bortolottia F, Indolfib G, Zancanc L, Giacchinod R, Verucchie G, Cammàf C, et al. Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades. Dig Liver Dis. 2011;43:325-329.

  68. Rosen I, Kori M, Eshach-Adiv O, Yerushalmi B, Zion N, Shaoul R. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C. World J Gastroenterol. 2013;19:1098-1103.

  69. Pawłowska M, Pilarczyk M, Halota W. Virologic response to treatment with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C in children. Med Sci Monit. 2010;16:CR616-CR621.

  70. Al Ali J, Owayed S, Al-Qabandi W, Husain K, Hasan F. Pegylated interferon a-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol. 2010;9:156-160.

  71. Wisniewska-Ligier M, Pawlowska M, Pilarczyk M, Halota W, Wozniakowska- Gesicka T. Efficacy of pegylated interferonalpha α-2b and ribavirin in chronic hepatitis C virus (genotypes 1and 4) infection. J Pediatr Gastroenterol Nutr. 2013;57 694-699.

  72. Suzuki M, Tajiri H, Tanaka Y, Takano T, Miyoshi Y, Murakami J, et al. Peginterferon therapy in children with chronic hepatitis C: a nationwide, multicenter study in Japan, 2004-2013. J Pediatr Gastroenterol Nutr. 2016;63:88-93.

  73. Zhong YW, Zhang HF, Shi YM, Li YL, Chu F, Xu ZQ, et al. IL28B SNP rs12979860 is the critical predictor for sustained viral response in Chinese children aged 1 to 6 years with chronic hepatitis C. Int J Biol Sci. 2016;12:1357-1362.

  74. Balistreri WF, Murray KF, Rosenthal P, Bansal S, Chuan-Hao L, Kersey K, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12 to 17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2016;66:371-378.

  75. Wirth S, Rosenthal P, González-Peralta RP, Jonas MM, Lin CH, Shao J, et al. Sofosbuvir and ribavirin in adolescents 12 to 17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017; 66:1102-1110.

  76. Fischler B, Priftakis P, Sundin M. Sofosbuvir and simeprevir treatment of a stem cell transplanted teenager with chronic hepatitis C infection. Pediatr Infect Dis J. 2016;35:708-710.

  77. Thomas P, Santiago T, Dallas MH. Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation. Bone Marrow Transplant. 2016;51:735-737.

  78. Smith SK, Rosenthal P. Clearance of hepatitis C virus after fixed-dose combination ledipasvir/sofosbuvir in an adolescent female with decompensated cirrhosis. J Pediatr Gastroenterol Nutr. 2016;63:516-517.

  79. Indolfi G, D’Antiga L. Treatment of hepatitis C virus infection in children: time for action. Liver Transpl. 2017;23:427-429.

  80. Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66:1102-1110.

  81. Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, et al. Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:505-515.

  82. A study to evaluate of hepatitis C virus infection in pediatric subjects (ZIRCON). EE. UU.: AbbVie; 2018.

  83. Abdel-Ghaffar TY. Treatment of Egyptian hepatitis C genotype 4 infected children (and adolescents) with combined sofosbuvir & daclatasvir. EE. UU.: Yassin Abdelghaffar Charity Center for Liver Disease and Research/Egyptian Cure Bank/Society of Friends of Liver Patients in the Arab World; 2018.

  84. Safety and efficacy of ledipasvir/sofosbuvir fixed dose combination +/- ribavirin in adolescents and children with chronic HCV-infection. EE. UU.: Gilead Sciences; 2018.

  85. Sofosbuvir/velpatasvir in adolescents and children with chronic HCV infection. EE. UU.: Gilead Sciences; 2018.

  86. Elbasvir (EBR)/grazoprevir (GZR) in pediatric participants with chronic hepatitis C infection (MK-5172-079). EE. UU.: Merck Sharp & Dohme Corp.; 2018.

  87. Efficacy and safety of ledipasvir/sofosbuvir fixed dose combination in the treatment of hepatitis C virus (HCV) infection in pediatric participants undergoing cancer chemotherapy (Egypt Peds). EE. UU.: Gilead Sciences; 2018.

  88. A study to evaluate the pharmacokinetics, safety, and efficacy of glecaprevir/ pibrentasvir in pediatric subjects with genotypes 1-6 chronic hepatitis C virus (HCV) infection (DORA). EE. UU.: AbbVie; 2018.

  89. Evaluation of daclatasvir (DCV) in combination with sofosbuvir (SOF) in children with chronic hepatitis C (CHC) infection. EE. UU.: Bristol-Myers Squibb; 2018.




2020     |     www.medigraphic.com